Madrigal Pharmaceuticals, Inc. MDGL
400.43 USD +4.11 (+1.04%)
At closeNov 4, 2026, 4:00 PM EST
398.70 -1.73 -0.43%
After hours · Nov 4, 4:00 PM ET
353.54 Day range 402.48
353.54 52-week range 615.00
- YTD
- -31.24%
- 1 year
- -15.85%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 686.06 +71.3% upside
Now 400.43
- Target (low)
- 479.00
- Target (mean)
- 686.06
- Target (high)
- 962.00
Ratings (0m) 19 18 buy · 1 hold · 0 sell
- Strong buy3
- Buy15
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 19
- 1 month ago 19
- 2 months ago 19
- 3 months ago 17
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.4225 | -0.77 – 0.11 | -2.57 | +83.6% | 480.87M | +49.8% | 4 |
| Next quarter | -0.755 | -1.83 – 0.32 | -1.38 | +45.3% | 454.51M | +46.0% | 2 |
| Current year | -6.49 | -7.38 – -4.91 | -12.73 | +49.0% | 1.59B | +65.7% | 4 |
| Next year | 9.63 | 7.01 – 12.84 | -6.49 | +248.3% | 2.17B | +36.6% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 4, 2026 | Truist Securities | Reiterated | Buy | Buy |
| Nov 3, 2026 | Citigroup | Maintained | Buy | Buy |
| Sep 23, 2026 | Citigroup | Initiated | — | Buy |
| Aug 4, 2026 | Wolfe Research | Upgrade | Peer Perform | Outperform |
| Aug 3, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jul 29, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Jul 27, 2026 | Wells Fargo | Initiated | — | Overweight |
| Jun 11, 2026 | B of A Securities | Maintained | Neutral | Neutral |
| May 13, 2026 | Truist Securities | Maintained | Buy | Buy |
| May 7, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| May 7, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| May 6, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 20, 2026 | B of A Securities | Maintained | Neutral | Neutral |
| Jan 28, 2026 | Barclays | Initiated | — | Overweight |
| Jan 20, 2026 | Citizens | Maintained | Market Outperform | Market Outperform |
| Dec 19, 2025 | Piper Sandler | Maintained | Overweight | Overweight |
| Dec 11, 2025 | B. Riley Securities | Maintained | Buy | Buy |
| Nov 21, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 20, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Nov 19, 2025 | Truist Securities | Maintained | Buy | Buy |
| Nov 13, 2025 | Canaccord Genuity | Maintained | Buy | Buy |
| Nov 11, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 5, 2025 | Cantor Fitzgerald | Upgrade | Neutral | Overweight |
| Nov 5, 2025 | Citizens | Maintained | Market Outperform | Market Outperform |
| Nov 3, 2025 | B of A Securities | Upgrade | Underperform | Neutral |
| Oct 15, 2025 | Piper Sandler | Maintained | Overweight | Overweight |
| Oct 15, 2025 | Truist Securities | Initiated | — | Buy |
| Oct 10, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Sep 29, 2025 | B. Riley Securities | Maintained | Buy | Buy |
| Sep 12, 2025 | Canaccord Genuity | Maintained | Buy | Buy |
